Clinical data | |
---|---|
Trade names | Cuprimine, Cuprenyl, Depen, others |
Other names |
|
AHFS/Drugs.com | Monograph |
MedlinePlus | a618021 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (capsules) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Variable |
Metabolism | Liver |
Elimination half-life | 1 hour |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.136 |
Chemical and physical data | |
Formula | C5H11NO2S |
Molar mass | 149.21 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Penicillamine, sold under the brand name of Cuprimine among others, is a medication primarily used for the treatment of Wilson's disease.[1] It is also used for people with kidney stones who have high urine cystine levels, rheumatoid arthritis, and various heavy metal poisonings.[1][2] It is taken by mouth.[2]
Penicillamine was approved for medical use in the United States in 1970.[1] It is on the World Health Organization's List of Essential Medicines.[3]
WHO2008
was invoked but never defined (see the help page).{{cite book}}
: CS1 maint: location missing publisher (link)